In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp.
Open Access
- 17 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 59 (3), 582-583
- https://doi.org/10.1093/jac/dkl514
Abstract
D. M. L. and N. W. have received grants and speaking invites from Merck, AstraZeneca and Wyeth; D. M. L. holds shares in AstraZeneca.Keywords
This publication has 6 references indexed in Scilit:
- Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from South-East EnglandJournal of Antimicrobial Chemotherapy, 2006
- In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagnostic Microbiology and Infectious Disease, 2005
- Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2005
- Effects of Efflux Transporter Genes on Susceptibility of Escherichia coli to Tigecycline (GAR-936)Antimicrobial Agents and Chemotherapy, 2004
- Mutations in the Interdomain Loop Region of thetetA(A) Tetracycline Resistance Gene Increase Efflux of Minocycline and GlycylcyclinesMicrobial Drug Resistance, 2000
- Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pumpAntimicrobial Agents and Chemotherapy, 1994